Is toxic build up causing stress to your cell membranes? Due to the lipid soluble or fatty nature of toxicity and the possible accumulation of these toxins in the cell membranes of brain tissue, could this be the cause of many neurological conditions such as in degenerative neurological diseases such as Parkinson’s? In fact this has been shown to be a significant problem associated with these conditions in the research. Examination of red cell lipids shows many chemicals, pesticides, biotoxins (from mold) and heavy metals in subjects with Motor Neuron Disease, Autism, Multiple Sclerosis, Post Stroke, Epilepsy, Alzheimer’s and Parkinson’s Disease. Thousands of analyses has revealed a characteristic accumulation of very long chain fatty acids (VLCFAs), which comprise lipid rafts, or ceramides, and can cause cell membrane derangement as well as poor cell signaling. Basically the cell membrane is so important that the accumulation of all these biotoxins, chemicals and heavy metals stored through these VLCFA’s cause significant dysfunction in the cells of the body but particularly in the brain. We are addressing this problem from a cell membrane perspective.
Membrane phospholipid abnormalities with elevation of VLCFAs may be indicative of exposure to fat soluble neurotoxins resulting in suppressed (peroxisomal beta oxidation of VLCFAs) or ability to create energy from fatty acids. Also many individuals have disturbances in methylation due to toxic exposure. This may further destabilize the membrane phospholipid structure (cell membrane) and alter DNA expression / Gene expression due to deficits in the enzymes Methylene Tetrahydrofolate Reductase (MTHFR) and Methionine Synthase. In other words toxic build up happens in the cell membranes and causes lots of problems. It is important to “turn over your cell membranes” which can be done through the specific program we have developed.
The use of oral and IV lipids may facilitate stabilization of phospholipids in cell membranes thereby addressing cell membrane integrity. The addition of intravenous phenylbutrate addresses neuroinflamation by increasing the beta oxidation of VLCFAs. See how Phenylbutrate is being studied for treatment for Parkinson’s Disease.
In order to detoxify the accumulation of toxins and stabilize cell membrane function, we have embarked on a clinical protocol to address the accumulation of aberrant lipids and ceramides with oral and IV phenylbutyrate, phosphatidylcholine, methylation factors (folinic acid, riboflavin, methylcobalamin), NAD and Glutathione.
The administration of Phosphatidylcholine, Phenylbutyrate, Methylation Support, NAD and Glutathione may offer a new therapeutic strategy for neurological disorders involving neurotoxic exposure, a significant cause of Parkinson’s disease!